Antibody evasion by the P.1 strain of SARS-CoV-2
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.03.12.435194: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Limitations of the study: The in vitro FRNT assays we report here do not measure the effect of complement or antibody dependent cell mediated cytotoxicity which may enhance neutralization in vivo. The role that T cells play in immunity to SARS-CoV-2 and in particular protection from severe disease is unknown and worthy of investigation, …
SciScore for 10.1101/2021.03.12.435194: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Limitations of the study: The in vitro FRNT assays we report here do not measure the effect of complement or antibody dependent cell mediated cytotoxicity which may enhance neutralization in vivo. The role that T cells play in immunity to SARS-CoV-2 and in particular protection from severe disease is unknown and worthy of investigation, but recent findings suggest that CD4 and CD8 T cell responses raised to ancestral strains are minimally impacted by the variants (Alison Tarke et al., 2021;Skelly et al., 2021). It will be interesting to determine the directionality of neutralization between the different variant viruses and naturally acquired antibody responses to them. For instance, there is some suggestion in this report that plasma induced by B.1.1.7 is better able to neutralize B.1.351 and P.1. Measuring neutralization of viral variants by B.1.351 and P.1 serum will give a better idea of cross protection against the other strains.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-
